Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar davemarriner (< 20) Submitted: 8/5/2010 11:34:59 AM : Outperform Start Price: $1.63 DVAX Score: +174.22

If current testing is successful.

Featured Broker Partners


Advertisement